Welcome to our dedicated page for UroGen Pharma Ltd. SEC filings (Ticker: URGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UroGen Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UroGen Pharma Ltd.'s regulatory disclosures and financial reporting.
Form 144 filed for UroGen Pharma Ltd. (URGN) reports a planned insider disposition.
- Securities: 5,149 ordinary shares.
- Estimated value: $97,573.55.
- Broker: Oppenheimer & Co., NASDAQ execution targeted for 28 Jul 2025.
- Total shares outstanding: 46,107,451; proposed sale equals ~0.011% of float.
- Share origin: Restricted Stock Units granted 31 Jan 2024 (10,000 units).
- Prior activity: Same seller disposed of 5,162 shares for $38,043.94 on 9 Jun 2025.
The filer certifies no undisclosed adverse information under Rule 144. Given the modest volume relative to outstanding shares, the transaction is unlikely to have a material price impact but continues a pattern of insider selling that investors may monitor.
UroGen Pharma Ltd. (URGN) – Form 144 filing. An unidentified insider has notified the SEC of an intended open-market sale of 7,522 ordinary shares through Oppenheimer & Co. on or after 28 Jul 2025. Based on the filer’s estimate, the block is worth $142,541.90, implying an indicative price of roughly $18.95 per share. The shares represent 0.016% of the company’s 46.1 million shares outstanding, a small fraction of float but still a required disclosure under Rule 144.
The shares stem from 16,500 restricted stock units granted and vested on 31 Jan 2024. The filer reports no other URGN share sales in the prior three months. The filer also certifies that no undisclosed material adverse information is known. While modest in size, the transaction flags upcoming insider liquidity and may be watched as a sentiment signal.